Migraine at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago

Here's a synopsis of Migraine research that was presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago April 12–19, 2008.

Migraine frequency linked with women's risk of cardiovascular disease
CHICAGO – New research shows women who have weekly migraine are significantly more likely to have a stroke than those with fewer migraines or no migraine at all, but those with lower migraine frequency may face increased risk of heart attacks. The research was presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12–19, 2008...
To read the entire article click HERE.

Children with migraine at increased risk of sleep disturbances
CHICAGO – Children with migraine are more likely to have sleep disorders, such as sleep apnea and lack of sleep, than children without migraine, according to research on the effects of headaches on children’s sleep patterns was presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12–19, 2008...
To read the entire article click HERE.

Overuse of codeine, oxycodone and barbiturates increases risk of chronic migraine
CHICAGO – People who overuse barbiturates and opioids, such as codeine, butalbital, and oxycodone, to treat migraine are at an increased risk of developing chronic migraine, according to research that was presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12–19, 2008. People with chronic migraine have headaches on 15 or more days a month...
To read the entire article click HERE.

New Hope for Migraine Sufferers: Optinose Nasal Delivery of Sumatriptan Proves as Effective as Invasive Subcutantaneous Injection
WASHINGTON--(BUSINESS WIRE)--At the American Academy of Neurology Annual Meeting, Optinose, the Norwegian drug delivery specialists, today presented Phase I data that could lead to faster, effective and less invasive relief for migraine sufferers. The recently completed trial first demonstrated that Sumatriptan powder delivered intranasally using OptiNose’s 2nd generation device has a rapid onset of action and is as effective as subcutaneously administered Sumatriptan in preventing GTN Challenge Induced EEG changes in migraine sufferers...
To read the entire article click HERE.

For more information about the American Academy of Neurology, visit www.aan.com.